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Apoptosis is a form of cell death which is regulated at the gene
level and plays a central role in cell number control during embry-
onic development and organogenesis; it determines the cellular
response to various physiological situations in adult tissues and
during pathophysiological conditions including neoplastic trans-
formation. In addition, defects in the apoptotic pathway may
represent a critical element in the progression of neoplastic disease
and may also concur to determine treatment efficacy at the cellular
level. In fact, many of the effects of the chemical and physical
agents that are commonly used in the treatment of human malig-
nancies are mediated by induction of apoptosis (Eastman, 1990;
Dive and Hickman, 1991; Schmitt and Lowe, 1999) and thus rely
at least in part on the same biochemical mechanisms involved
in physiological cell death control. As a consequence, genetic
alterations that prevent or delay normal cell turnover may also
be responsible for treatment inefficacy in tumour cells. 
Bax and bcl-2 are members of the large family of proteins that
constitute a critical intracellular checkpoint within a common cell
death pathway involved in determining the susceptibility of cells
to undergo apoptosis. This checkpoint is controlled by the ratio
between promoters (i.e. bax) and inhibitors (i.e. bcl-2) of cell
death and although these molecules compete through dimeriza-
tion, extensive mutational studies have not been able to establish
whether their function is interdependent or whether either agonists
or antagonists are dominant (Sionov and Haupt, 1999). 
Bcl-2 protein expression or gene activation have been associated
with poor response to therapy and/or shorter disease-free survival in
some groups of patients with lymphomas (Yunis et al, 1989),
leukaemias (Campos et al, 1993), prostate cancer (McDonnel et al,
1992) and breast cancer (Bonetti et al, 1998; Daidone et al, 1999). In
head and neck tumours on the other hand bcl-2 positivity proved to
be either highly indicative (Gasparini et al, 1995, Homma et al,
1999) or independent (Costa et al, 1998) of the response to treat-
ment. A poor response to chemotherapy and short survival was
observed in a subgroup of patients with metastatic breast cancer
whose tumours showed reduced bax immunostaining (Krajewski et
al, 1995). Similarly, it was shown that high bax expression in
ovarian cancer was associated with a significant increase in the
percentage of complete remissions after first-line chemotherapy
including paclitaxel and a platinum analogue, and also with an
improvement in survival (Tai et al, 1998), although such findings are
not universal (Silvestrini et al, 1998). 
In patients with advanced or metastatic colorectal cancer
chemotherapy with fluorouracil plus leucovorin (5-FU/LV)
provides an overall response rate of approximately 25% with a
limited effect on survival (Clark, 1997). As a consequence, alter-
native agents and new treatment strategies or combinations are
being investigated. Research efforts have increased our under-
standing of how anticancer agents mediate their effects, and
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tumour type have been identified. However, in advanced
colorectal cancer the search for indicators of response to
chemotherapy still represents a valuable effort to potentially
improve the therapeutic decision-making following failure to first-
line therapies. 
We have analysed the expression of bax and bcl-2 in a group of
84 patients with recurrent or metastatic colorectal cancer, homo-
geneously treated with the same polychemotherapy regimen, in an
attempt to elicit the role of apoptosis-related markers as indicators
of clinical outcome. Moreover, the expression pattern of bax and
bcl-2 was analysed in comparison with that of p53, which had
previously been determined in the present case series (Paradiso 
et al, 1996), and their interactions were investigated in relation 
to clinical outcome. Since morphological analysis appears the
unequivocal gold standard (Hall, 1999) for the assessment and
quantitation of apoptosis, in a subset of 48 patients of the present
series we determined the apoptotic index (AI) as defined by the
TUNEL technique (Gavrieli et al, 1992). The relationship between
AI and the expression of the apoptosis-related proteins bax, bcl-2
and p53 was examined and its potential clinical role in terms of
response to treatment, time to progression and overall survival was
analysed. 
MATERIAL AND METHODS 
Patients and treatment 
Treatment modalities and inclusion criteria of the patients
involved in this study have been described in detail elsewhere
(Machiavelli et al, 1991; Paradiso et al, 1996). All patients had
advanced disease at first diagnosis or recurrent disease and had 
not been previously treated with any systemic chemotherapy.
Briefly, formalin-fixed, paraffin-embedded samples of surgically
resected primary colorectal cancer from 84 patients participating
in the treatment protocols of the institutions of GOCS-Argentina
(Machiavelli et al, 1991) were available for retrospective bio-
logical characterization. Patients received methotrexate (MTX) at
200 mg/m2 intravenously (i.v.) by push injection followed by 5-FU
at 1200 mg/m2 as a continuous i.v. infusion over 2 h; 24 h after
MTX administration all patients received 25 mg LV every 6 h for a
total of 8 doses. The treatment schedule was repeated every 15
days until disease progression, severe toxicity or death. Patients
were considered evaluable for response when they had received at
least 2 chemotherapy cycles. Standard UICC criteria were used for
evaluation of clinical response, and objective regression (OR)
included complete remission (CR) and partial response (PR). 
Immunohistochemical staining for bax and bcl-2
proteins 
Immunohistochemical staining was performed on tissue sections
of formalin-fixed, paraffin-embedded surgical specimens from
primary tumours. The 4-mm-thick slices were deparaffinized in
xylene, dehydrated with graded ethanol and submitted to
microwave irradiation for 10 min in 10 mM citrate buffer (pH 6.0)
to detect masked and unmasked antigen sites. 
bax expression 
The microwave-treated sections were incubated for 2 h at 4˚C with
a 1:400 dilution of polyclonal rabbit antibody bax N-20 (Santa
Cruz Biotechnology Inc, Santa Cruz, CA) as previously described
(Costa et al, 1998). After incubation the specimens were treated
with a biotinylated anti-rabbit immunoglobulin and processed
using immunoperoxidase staining (Vectastain ABC Kit). The
quality of the bax antiserum used batch was assessed by Western
blot analysis on human colorectal cancer cell lines. 
bcl-2 expression 
The microwave-treated sections were incubated for 1 h at room
temperature in a humidified atmosphere with a 1:40 dilution of
monoclonal mouse anti-human bcl-2 oncoprotein (clone 124;
Dakopatts, Copenhagen, Denmark), as previously described
(Costa et al, 1998). As with bax, the ABC immunoperoxidase
system was used. 
Colorectal cancers with high bax or bcl-2 immunoreactivity
were used as positive controls, whereas negative controls for the
markers were obtained by omission of the primary antibody.
Positivity for bax and bcl-2 was present when unequivocal brown
staining was observed in tumour cells at the cytoplasmic level, and
semiquantitative measurement was performed by scoring a total of
1000 to 3000 tumour cells of the same sample.
p53 expression 
In the present series p53-protein expression had been determined
as part of a previous study, which includes a detailed description of
the method (Paradiso et al, 1996). Briefly, microwave-treated
sections were incubated for 1 h at room temperature with a 1:50
dilution of PAb1801 monoclonal antibody (Oncogene Science,
Inc, Manhasset, NY). The monoclonal antibody, raised against
human p53, recognizes wild-type and mutant forms of the p53
protein. 
Evaluation of the biomarkers was performed independently by
two observers who were unaware of the clinical outcome. The
determination of bcl-2 and p53 expression was performed within
National Quality Control Programs (Finalized Project 98/90,
Ministry of Health, Italy). In the overall series of 84 cases, infor-
mation was available on bax and bcl-2 protein expression for all
tumours, whereas p53 protein expression determination was avail-
able for 83 cases. 
Apoptotic index assessment 
Apoptotic cells and apoptotic bodies were detected in a subset of
48 cases with adequate tumour material following previous deter-
minations from the overall series of 84 tumours using the In Situ
Cell Death Detection Kit, POD (Boehringer Mannheim GmbH,
Biochemica, Germany), an indirect TUNEL labelling assay.
Briefly, deparaffinized and rehydrated sections were digested
with protease K (1 mg ml–1 in PBS; Sigma-Aldrich S.r.l., Milan,
Italy) for 15 min at 37˚C and washed. After quenching in 3%
hydrogen peroxide for 10 min, washing with PBS, and adding the
equilibration buffer for 10 min, the sections were incubated at
37˚C for 1 h with terminal deoxynucleotidyl transferase enzyme.
After the reaction had been stopped by placing the sections in
stop/wash buffer and washing them, anti-digoxigenin-peroxidase
was added to the slides. Finally, the slides were washed with PBS,
stained with diaminobenzidine (Dakopatts) substrate, and coun-
terstained with haematoxylin. A positive control was prepared by
nicking DNA with DNase I (1 mg ml–1; Sigma-Aldrich S.r.l.) for
the first staining procedure. A specimen known to be positive 
for apoptotic cells was used as positive control for subsequent
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with distilled water was used as negative control. AI was
expressed as the ratio of positive-staining tumour cells and bodies
to all tumour cells and was given as a percentage for each case.
Necrotic areas and positive cells located in the stroma and lumen
were avoided as they could have originated from other cell types.
A minimum of 3000 cells was counted using 400-fold magnifica-
tion. Positive-staining tumour cells with the morphological char-
acteristics of apoptosis were identified using standard criteria
including chromatin condensation, nuclear disintegration, and
formation of crescentic caps of condensed chromatin at the
nuclear periphery. 
Statistical analysis 
For basic analysis, bax, bcl-2 and p53 expression and AI were
considered as continuous variables and their relationship was
investigated by Spearman’s regression coefficient (rs). The associ-
ation between bax and bcl-2 expression, AI and clinicopatholo-
gical features was assessed by means of Wilcoxon’s rank-sum test. 
When bax, bcl-2 and p53 expression was related to clinical
outcome, biomarkers were considered as dichotomous variables
by taking as the cutoff for negativity/positivity the value of 5%
stained cells. For p53 in colorectal cancer such a cutoff value
provided the best concordance between mutational status and
protein accumulation evaluated by immunohistochemistry (Costa
et al, 1995). The median value of 0.6% was used as a cutoff
between low and high AI. The association between biomarkers, AI
and clinical response was evaluated by the chi-square test, con-
tinuity adjusted when appropriate. 
Time to progression (TTP) and overall survival (OS) were
calculated as the interval between the date of initiation of treat-
ment and the date of first progression (local progression or distant
metastasis) or the date of death (or of the last follow-up for
censored observations), and were estimated by the Kaplan–Meier
product-limit method. The influence of the biomarkers on TTP and
OS was evaluated by fitting a Cox regression model. Hazard ratios
(HR) and their 95% confidence limits (CL) were determined using
the putative best prognostic category as a reference. At the time of
the present analyses, 67 patients progressed or developed distant
metastases and 53 patients died. The median OS for surviving
patients was 13 months (range, 1 to 52 months). 
RESULTS 
Immunostaining of apoptosis-related markers 
Positive immunoreactivity for bax and bcl-2 was localized in the
cytoplasm of tumour cells, and most tumours that were scored as
positive showed homogenous intensity of immunostaining. Bax or
bcl-2 immunostaining was present in residual normal epithelial cells
or infiltrating lymphocytes and these non-malignant cells were an
internal positive control to verify adequate specimen preservation 
in non-immunoreactive malignant tissues. 55 of the 84 tumours
(65.5%) showed more than 5% bax-immunopositive cells (bax+), and
the median fraction of bax-expressing cells in bax+tumours was 79%
(range, 10–100%). For bcl-2 protein expression, 38% of tumours
(32/84 cases) showed more than 5% bcl-2-positive cells (bcl-2+), and
the median fraction of bcl-2 expressing cells in bcl-2+ tumours was
40% (range, 10–80%). In the 83 cases for which also p53 protein
expression had been determined, nuclear immunoreactivity in more
than 5% of tumour cells (p53+) was observed in 39% of tumours
(32/83 cases), with a median value of 40% immunoreactive cells in
p53+ cases (range, 10–100%). Apoptotic cells and apoptotic bodies
were detected in all 48 colorectal caracinomas examined by in situ
labelling, and the median AI was 0.6% (range, 0.02–5.9%). 
Bax, bcl-2 and p53 proved to be expressed independently of
each other, as shown by the very low correlation coefficients (bax
vs bcl-2, rs = –0.02; bax vs p53, rs = 0.13; bcl-2 vs p53, rs = 0.18).
In addition, a similar distribution of bax and bcl-2 immunoreactive
cells was observed as a function of p53 expression. In fact, the
same median frequency of bax+ cells (65%) was observed in 
p53– and p53+ tumours, and bcl-2 immunoreactivity was not statis-
tically different in the p53– (median bcl-2+ cells, 30%) and p53+
(median bcl-2+ cells, 60%) tumour subsets. Moreover, AI was
unrelated to bax, bcl-2 and p53 expression. 
In the present series of patients, as previously reported for 
p53 protein (Paradiso et al, 1996), the expression of the two 
apoptosis-related proteins was independent of those patient and
tumour features that are conventionally indicative of clinical
outcome for this neoplasm, i.e. patient age, site of the primary
tumour, time of disease (first diagnosis vs recurrence), type of
metastases (site and number) and histological grade. Also, AI was
not significantly associated with any of the clinicopathological
factors. 
Clinical outcome as a function of biomarkers 
80 of the 84 patients who entered the study received more than 2
cycles of chemotherapy; an OR was reached in 25% of these cases
whereas 35% (28/80) had progressive disease, and the remaining
32 patients had stable disease during treatment. At 24 months from
the start of treatment the probability of being free of progression
was only 2% and the median time to progression was 11, 8 and 3
months, respectively, for patients having OR, stable disease or
disease progression during treatment. The probability of being
alive at 24 months from the start of treatment was 39%, 38% and
0%, respectively, for the 3 subsets of patients. 
In Table 1 the response rates are analysed as a function of the
different bax and bcl-2 immunocytochemical patterns. Objective
clinical response was not related to the expression of bax or bcl-2,
even though 15 of the 20 patients who achieved an OR had a bcl-
2-tumour. When the combined bax/bcl-2 patterns of immunos-
taining were examined, the two markers again did not appear
associated with the response rate following MTX and 5-FU/LV
treatment (data not shown). In the subset of patients for whom AI
was determined, a (not statistically significant) trend towards an
association between apoptosis and response to treatment was
observed (Table 1). A high AI (³0.6%) was observed in 7 of the 10
patients achieving objective response, whereas a low AI (<0.6%)
was observed in 10 of 15 patients with progressive disease. 
Univariate analysis showed that 2-year TTP and OS were inde-
pendent of apoptosis-related markers (Figure 1) and the survival
curves were almost superimposable for subsets defined according
to the expression of bax or bcl-2, except for patients with bax+
tumours, whose median survival time was slightly shorter than that
observed for patients with bax- tumours (9 vs 14 months). The
trend in favour of an association between AI and response to treat-
ment was not reflected by the 2-year clinical outcome. In fact, the
presence of high or low AI did not segregate subsets of patients at
different prognosis in terms of TTP and OS (data not shown). 
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markers on clinical outcome was performed by considering in
association p53 and bax or bcl-2 expression. Since these results
were derived from subset analyses, comparisons between the
proposed subgroups were meant to be descriptive, preliminary and
hypothesis-generating only. The highest response rates (Table 2)
were observed within the subgroup of patients with p53- tumours
which did not express bax or bcl-2 proteins (40% and 34%, respec-
tively). With respect to OS, p53 protein expression was not indic-
ative of clinical outcome for this selected series of patients with
advanced colorectal cancer (Paradiso et al, 1996), although a
combined analysis that considered bax and bcl-2 expression iden-
tified a small subgroup of 8 patients with bax–/p53+ tumours with a
75% probability of being alive at 2 years as compared to the 
lower probabilities found for the remaining subgroups of patients
(Table 2). 
DISCUSSION 
In the present study we evaluated the association between clinical
outcome and the expression of markers related to the apoptotic
process in a group of patients with recurrent or metastatic colorectal
adenocarcinoma previously characterized for p53 and treated with a
polychemotherapy regimen that included MTX and 5-FU/LV.
Among the different approaches to evaluate cell susceptibility to the
activation of apoptosis, we focused on the expression of two neg-
ative and positive regulatory proteins, bcl-2 and bax, whose immuno-
cytochemical determination proved to be feasible on archival
specimens and associated with tumour progression and treatment
response in different clinical situations involving various tumour
types (Krajewski et al, 1995; Barretton et al, 1996; Apolinario et al,
1997; Bonetti et al, 1998; Silvestrini et al, 1998; Tai et al, 1998;
Daidone et al, 1999; Ogura et al, 1999; Sturm et al, 1999). Bax
represents a pro-apoptotic member of the bcl-2 family which
controls important checkpoints during the apoptotic process and
whose transcriptional activation is induced by wild-type p53. Thus,
cancer may arise through selective loss of an apoptotic pathway as a
result of the replication of cells that survived DNA damage or other
severe intracellular injury. This could explain the reason why cancer
cells arising in this way are resistant to many cytotoxic agents
because of loss of critical functions in the control of cell number. 
To our knowledge only two studies have evaluated the pro-
gnostic relevance of the apoptosis promoter bax in patients with
resectable primary colorectal cancer (Ogura et al, 1999) and liver
metastases from colorectal cancer (Sturm et al, 1999) submitted to
surgery without any adjuvant treatment. In both studies bax expres-
sion and/or mutational status proved to be significantly related to
clinical outcome. In fact, in these studies involving 58 (Ogura et al,
1999) and 41 (Sturm et al, 1999) patients, those with high bax
protein expression had a longer survival than patients with low bax
expression, and this finding was especially evident for patients with
wild-type p53 liver metastases (Sturm et al, 1999). However, in a
group of patients submitted to preoperative radiochemotherapy for
locally advanced rectal carcinoma Tannapfel et al (1998) did not
find any correlation between the level of bax expression and the
degree of clinical-to-pathological downstaging or the frequency of
tumour recurrence. In the present study, for the first time in patients
with metastatic colorectal cancer submitted to a polychemotherapy
regimen, the predictive role of the pro-apoptotic protein bax and the
anti-apoptotic protein bcl-2 was analysed in terms of response to
treatment and overall survival. In our series of metastatic and recur-
rent cancer patients, bax protein expression itself did not appear to
divide patients into different groups with respect to clinical disease
course. Different explanations might account for this finding: 1)
treatment might mask the clinical role of bax expression; 2) the
aggressive behaviour of advanced disease prevails over the relev-
ance of biological markers for tumour progression or treatment
response; 3) the multifactorial nature of intrinsic resistance to
antimetabolites and the complex cascade of intracellular signals
controlling the activation and progression of the apoptotic
programme make it inappropriate to ascribe a great deal of func-
tional significance on the basis of the evaluation of a single gene
product such as bax. The last finding prompted us to investigate the
information provided by bax, an apoptosis promoter, with that
provided by bcl-2, an apoptosis suppressor. 
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Table 2 Clinical outcome as a function of bax and bcl-2 in advanced
colorectal adenocarcinomas with different p53 expression 
% of OR (no. cases) 2-yr probability of OS
p53– p53+ p53– p53+
bax– 40 (8/20) 13 (1/8) 21 75 
bax+ 21 (6/29) 22 (5/23) 33 25 
bcl-2– 34 (11/32) 21 (4/19) 29 27 
bcl-2+ 18 (3/17) 17 (2/12) 28 30 
OR, objective regression; OS, overall survival 
Table 1 Relationship between response to polychemotherapy including MTX and 5-FU/LV and apoptosis-related
markers in patients with advanced colorectal adenocarcinomas 
Total Objective regression Stable disease Progressive disease 
No. of cases (%) No. of cases (%) No. of cases (%) 
bax expressiona
Negative 28 9 (32%) 11 (39%) 8 (29%) 
Positive 52 11 (21%) 21 (40%) 20 (39%) 
bcl-2 expressionb
Negative 51 15 (30%) 20 (39%) 16 (31%) 
Positive 29 5 (18%) 12 (41%) 12 (41%) 
AIc
<0.6% 23 3 (14%) 10 (43%) 10 (43%) 
³0.6% 23 7 (30%) 11 (48%) 5 (22%) 
achi square = 1.393, P = 0.50; bchi square = 1.646, P = 0.44; cchi square = 3.314, P = 0.19 Previous reports on colorectal carcinoma established an associa-
tion between bcl-2 positive staining and good prognosis (Ofner 
et al, 1995; Baretton et al, 1996), suggesting that bcl-2 promoted
cell survival in slowly growing tumours, which was recently
confirmed by Ogura et al (1999) and is in keeping with results
obtained in other solid tumours (Silvestrini et al, 1994). All these
studies, however, referred to patients with operable colorectal
cancer submitted to surgery as the only therapeutic approach. By
contrast, in the present series of advanced colorectal patients bcl-2
expression was not indicative of clinical outcome, which is in
agreement with the results of a previous study on liver metastases
from colorectal cancer (Costa et al, 1997). The only clinically 
relevant observation was the high objective regression rate
observed in patients with bcl-2-negative lesions, in agreement 
with data reported in other solid tumours such as prostate cancer
(McDonnell et al, 1992) and breast cancer (Bonetti et al, 1998),
and in systemic diseases such as lymphomas (Yunis et al, 1989)
and leukaemias (Campos et al, 1993). 
In in vitro experiments high endogenous levels and gene
transfer-mediated overexpression of bax have been correlated 
with increased sensitivity to apoptosis induced by chemothera-
peutic drugs (Bargou et al, 1995, 1996). Conversely, gene transfer-
mediated elevations in bcl-2 have been shown to promote in vitro
resistance to a number of drugs, including anthracyclines (Teixeira
et al, 1995) and some antimetabolites (Orlandi et al, 1999). Thus,
if one considers the combined pattern of bax/bcl-2 expression one
would expect tumours with high bax and low bcl-2 expression to
exhibit a higher response rate or a more favourable outcome
bcl-2, bax and p53 in advanced colorectal cancer 655
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Figure 1 Clinical outcome, i.e., time to progression (TTP) and overall survival (OS), in patients with advanced colorectal cancer as a function of bax (log-rank
test: TTP, P = 0.79; OS, P = 0.30) and bcl-2 (log-rank test: TTP = 0.96; OS, P = 0.40) protein expressionfollowing chemotherapy, as was also observed in other tumour
types (Krajewski et al, 1995; Daidone et al, 1999). However, this
hypothesis was not supported by the results obtained in the present
series of patients, which would suggest that in intrinsic chemo-
resistance of colorectal cancer the contribution of drug-induced
damage to the activation of apoptosis needs to be investigated at
different levels in pre- and post-treatment specimens, possibly
extending the research to the detection of proteins that can influ-
ence apoptosis in certain instances through positive or negative
regulation. 
In our study, contrary to what was observed in other tumour
types (Silvestrini et al, 1994; Krajewski et al, 1995; Apolinario 
et al, 1997), no relationship was found between p53 and bax or
bcl-2 protein expression, i.e., cases not expressing p53 did not
present any clear upregulation of bax or downregulation of bcl-2.
This finding could imply that bax or bcl-2 might be regulated by
mechanisms other than p53, as already reported with regard to
colorectal tumours (De Angelis et al, 1998) and other tumour types
including breast cancer (Daidone et al, 1999), non-small-cell lung
cancer (Apolinario et al, 1997), squamous cell carcinoma of the
larynx (Fracchiolla et al, 1999) and of the oral cavity (Costa et al,
1998). Generally, no relationship was observed between clinical
outcome and p53/bax or p53/bcl-2 staining patterns, except for a
high response rate (42%) in patients with p53–/bax– tumours. This
as well as other findings derived from subset analysis should be
considered as hypothesis generating and therefore need to be vali-
dated. However, the paradoxical observation of loss of bax corre-
lated with a trend towards a better prognosis could be the
consequence of the potential presence of a microsatellite mutator
phenotype (MMP). In fact, bax expression can be lost upon
frameshift mutations in a tract of 8 deoxyguanosines in the bax
gene, frequently present in MMP (Rampino et al, 1997; Abdel-
Rahman et al, 1999). It has been reported that the MMP in
colorectal cancer is associated with response to 5-FU treatment
(Nelson, 1998), and that patients with mismatch repair deficiency
have a better clinical outcome (Bubb et al, 1996; Forster et al,
1998; Lukish et al, 1998; Liang et al, 1999). 
Since intrinsic drug resistance may be the biological equivalent
of resistance to apoptosis induction, in addition to the biomarkers
studied we examined the apoptotic index with the TUNEL method
in order to detect apoptotic cells in a subset of the present series of
tumours. No significant association was found between AI and the
expression of the proteins studied, as was also previously reported
in colorectal carcinoma by other authors (Takano et al, 1996;
Matsuura et al, 2000; Tenjo et al, 2000), our results could not
confirm the significance of the p53 gene status in the induction of
apoptosis in colorectal carcinomas. This might have been partly
due to the small number of cases examined, or it might imply the
predominance of a p53-independent pathway in the induction of
apoptosis in human colorectal carcinomas. Again, AI did not
exhibit the expected correlation with bax and bcl-2 protein expres-
sion, as was also reported for gastric (Sugamura et al, 1997) and
colorectal (Langlois et al, 1997) cancers. However, these findings
are in keeping with the hypothesis that in a proportion of
colorectal cancer cases the bcl-2 proto-oncogene expression may
be downregulated at a post-transcriptional level (Berney et al,
2000) since the expression of bcl-2 protein was gradually and
significantly lost during the progression from moderately
dysplastic adenoma to primary colorectal carcinoma; conversely,
the cellular expression of bcl-2 mRNA gradually increased during
the successive steps of carcinogenesis. 
A prognostic role of the AI has been postulated for patients with
colorectal cancer, underlying an aggressive pattern in presence of
a low frequency of apoptotic cells (Langlois et al, 1997; Kawasaki
et al, 1998; Sugamura et al, 1998; Tenjo et al, 2000). It was
recently demonstrated that preoperative treatment with tegafur (a
prodrug of 5-FU) (Matsuura et al, 2000) or 5-FU (Yamane et al,
1999) enhances apoptosis in human colorectal carcinoma, and that
an increase in the apoptotic index after short-term cytostatic treat-
ment is associated with objective responses in patients with rectal
cancer (Farczadi et al, 1999). Similarly, we observed a direct rela-
tion between AI and response to a polychemotherapy regimen
including 5-FU, suggesting that the morphological evaluation of
the apoptotic status may provide information on treatment
response. This finding is lost on the long-term clinical outcome,
but it is worth mentioning that in advanced and metastatic disease
the intrinsic aggressive phenotype might overcome the predict-
ive/prognostic role of single biomarkers. 
In conclusion, in the present series of patients with metastatic
colorectal cancer we did not find clinically relevant associations
between markers favouring, delaying or controlling apoptosis
such as bax, bcl-2 and p53, and response to a polychemotherapy
regimen including MTX and 5-FU/LV. It must be pointed out,
however, that in spite of objective clinical responses achieved in
25% of cases, almost all patients developed disease progression
within 2 years from the start of treatment, which emphasizes the
known aggressiveness and resistance to chemotherapy of this
disease at the advanced stages. To overcome the present limita-
tions of commonly used drug-resistance markers which do not
satisfactorily predict the clinical outcome of specific subsets of
patients, much effort is needed to better identify specific
markers of drug action. In this respect promising results seem
achievable by analysis of the expression of thymidylate
synthase, a crucial enzyme for de novo synthesis of thymidine
which is specifically inhibited by 5-FU (Johnston et al, 1991;
Paradiso et al, 2000). 
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